Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Tax Provisions (2022 - 2026)

Centessa Pharmaceuticals has reported Tax Provisions over the past 4 years, most recently at -$522000.0 for Q4 2025.

  • Quarterly Tax Provisions fell 149.71% to -$522000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, down 36.04% year-over-year, with the annual reading at $1.8 million for FY2025, 36.04% down from the prior year.
  • Tax Provisions was -$522000.0 for Q4 2025 at Centessa Pharmaceuticals, down from $166000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $1.4 million in Q1 2025 and troughed at -$24.1 million in Q2 2023.
  • The 4-year median for Tax Provisions is $323500.0 (2024), against an average of -$1.3 million.
  • The largest YoY upside for Tax Provisions was 746.25% in 2023 against a maximum downside of 109222.73% in 2023.
  • A 4-year view of Tax Provisions shows it stood at -$664000.0 in 2022, then soared by 272.29% to $1.1 million in 2023, then decreased by 8.22% to $1.0 million in 2024, then crashed by 149.71% to -$522000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Tax Provisions are -$522000.0 (Q4 2025), $166000.0 (Q3 2025), and $778000.0 (Q2 2025).